This is a preliminary, multicenter, retrospective cohort study, including 272 consecutive patients with COVID-19 admitted to hospitals in Buenos Aires Province, between May 15th and July 1st, 2020, included in an expanded access program to convalescent plasma Our objectives were to analyze mortality and its independent risk factors, and to assess the occurrence of a favorable evolution, defined as hospital discharge, or stay at the ward, or transfer from ICU to ward Patients were stratified int o 4 subgroups: admission to the ward with pneumonia and/or oxygen requirement (WARD;n = 100);ICU admission (ICU;n = 87);ICU admission with requirement of mechanical ventilation (ICU-MV;n = 56), and ICU-MV plus septic shock (ICU-MV-SS;N = 29) Mortality at 28 days was 26 1% for the entire group, 14 0% for WARD group, 18 4% for ICU, 44 6% for ICU-MV, and 55 2% for ICU-MV-SS Mean survival time (days) was 25 6 ± 0 6 (WARD);25 3 ± 0 7 (ICU);20 8 ± 1 2 (ICU-MV) and 18 2 ± 1 8 (ICU-MV-SS) Independent predictors of mortality were MV, septic shock and weight A favorable evolution occurred in 81 4% of WARD patients;in 70 9% of ICU;in 39 6% of ICU-MV and in 27 6% of ICU-MV-SS patients Severity of illness on admission, age, weight and heart rate were independently associated with evolution No major adverse effects were recorded The lack of a control group precluded the estimation of efficacy However, our 26% mortality rate was higher than that of the treatment arm of clinical trials comparing plasma with usual treatment, which might be ascribed to higher proportion of patients with MV and septic shock in our cohort
[Convalescent plasma therapy in COVID-19 patients, in the Province of Buenos Aires]